Celltrion posted its highest quarterly performance ever. Based on growth trends in major global markets such as the United States and Europe, both revenue and operating profit set new records for a single quarter.
On the 12th, Celltrion announced that its consolidated revenue for the third quarter of this year reached 1.5 trillion won, up 45.8% from the same period last year. Operating profit rose 69.2% to 510 billion won during the same period. This marks the first time Celltrion's quarterly operating profit has surpassed 500 billion won. The company has exceeded its operating profit targets, disclosed in its annual business and management plan at the beginning of the year, for three consecutive quarters, proving its profit growth plans with actual results.
Celltrion is creating a virtuous cycle of improving operating profit by combining economies of scale from increased revenue with efficiency improvements in selling, general, and administrative expenses (SG&A). While maintaining the sales base of existing products such as the autoimmune disease treatment "Remsima" and the blood cancer treatment "Truxima," the company has continuously added new products, expanding its biosimilar portfolio to 11 items. In particular, in major global markets like the United States and Europe, the direct sales networks and business channels established for existing products are extending to subsequent products, strengthening sales synergy across the entire portfolio.
In Europe, autoimmune disease treatments such as Remsima, its subcutaneous (SC) formulation "Remsima SC," and "Uplyma" are showing concrete results, along with the allergy treatment "Omrilok," which was launched as a first-mover, and the autoimmune disease treatment "Aptozuma." In particular, Omrilok, sold in 26 European countries, has a market share approaching 90% in Spain as of last July. The company is also expanding its market influence by successfully winning national tenders not only in the EU5 (Germany, France, Italy, Spain, and the United Kingdom) but also in Norway, Denmark, and other countries.
In the United States, Truxima and "Inflectra" (the U.S. product name for Remsima) maintained solid market shares of 39% and 31%, respectively, as of last August. Meanwhile, growth is rapid among autoimmune disease treatments such as the SC formulation "Zymfentra" (the U.S. product name for Remsima SC), "Stelara," and "Uplyma." In addition, following the launch of Omrilok in the United States as a first-mover earlier this month, it was listed as a "preferred drug" in the formulary of Optum, one of the top three U.S. pharmacy benefit managers (PBMs), raising expectations for expanded prescriptions based on secured reimbursement.
Under the principle of "returning one-third of consolidated net income to shareholders," Celltrion has purchased 400 billion won worth of its own shares this year alone, expressing confidence in its medium- and long-term growth.
A Celltrion official stated, "As we simultaneously expand the sales share of high-profit products and improve our cost structure, the trend of improving profitability—where revenue growth translates into profit growth—has become even clearer." The official added, "Based on growth drivers such as the U.S. launch of Omrilok and expanded supply in Europe, we will do our utmost to achieve our fourth-quarter and annual business plan (revenue of 5.3 trillion won, operating profit of 1.8 trillion won)."
in THEBIO
